Evidence map›Paper›PMID 31002103›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Cost-Effectiveness Analysis of Integrated Care in Management of Advanced Chronic Obstructive Pulmonary Disease (COPD).

Ewa Bandurska, Iwona Damps-Konstańska, Piotr Popowski, Tadeusz Jędrzejczyk, Piotr Janowiak, Katarzyna Świętnicka, Marzena Zarzeczna-Baran, Ewa Jassem

Abstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Efficiency and Effectiveness of Patient Care Provided by Physicians in Rural and Urban Areas in Poland.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Serum Levels of Gamma-Glutamyltransferase During Stable and Acute Exacerbations of Chronic Obstructive Pulmonary Disease.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ewa BandurskaDepartment of Public Health and Social Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Iwona Damps-KonstańskaDepartment of Allergology, Medical University of Gdańsk, Gdańsk, Poland.
Piotr PopowskiDepartment of Public Health and Social Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Tadeusz JędrzejczykNational Health Fund, Warsaw, Poland.
Piotr JanowiakDepartment of Allergology, Medical University of Gdańsk, Gdańsk, Poland.
Katarzyna ŚwiętnickaUniversity Clinical Center in Gdańsk, Gdańsk, Poland.
Marzena Zarzeczna-BaranDepartment of Public Health and Social Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Ewa JassemDepartment of Allergology, Medical University of Gdańsk, Gdańsk, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Chronic obstructive pulmonary disease (COPD) is a common disease that occurs all over the world. Models of care, initially accessed from the clinical point of view, must also be evaluated in terms of their economic effectiveness, as health care systems are limited. The Integrated Care Model (ICM) is a procedure dedicated to patients suffering from advanced COPD that offers home-oriented support from a multidisciplinary team. The main aim of the present study was to evaluate the cost-effectiveness of the ICM. MATERIAL AND METHODS We included 44 patients in the study (31 males, 13 females) with an average age 72 years (Me=71). Costs of care were estimated based on data received from public payer records and included general costs, COPD-related costs, and exacerbation-related costs. To evaluate cost-effectiveness, cost-effectiveness analysis (CEA) was used. The incremental cost-effectiveness ratio (ICER) was calculated based on changes in health care resources utilization and the value of costs observed in 2 consecutive 6-month periods before and after introducing ICM. RESULTS Costs of care of all types decreased after introducing ICM. Demand for ambulatory visits changed significantly (p=0.037) together with a substantial decrease in the number of emergency department appointments and hospitalizations (p=0.033). ICER was more profitable for integrated care than for standard care when assessing costs of avoiding negative parameters such as hospitalizations (-227 EUR), exacerbations-related hospitalizations (-312 EUR), or emergency procedures (-119 EUR). CONCLUSIONS ICM is a procedure that meets the criteria of cost-effectiveness. It allows for avoiding negative parameters such as unplanned hospitalizations with higher economic effectiveness than the standard type of care used in managing COPD.

Indexed as

AgedCost-Benefit AnalysisDelivery of Health Care, IntegratedDisease ProgressionFemaleHealth Care CostsHospitalizationHumansMaleManaged Care ProgramsMiddle AgedModels, EconometricPolandPulmonary Disease, Chronic Obstructive

Identifiers

PMID31002103
PMCPMC6486702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.